rabbit anti human cd4 monoclonal antibody  (Boster Bio)

Journal: Translational Cancer Research

Article Title: Ovarian teratomas causing anti-N-methyl-D-aspartate receptor encephalitis: a case series from west China

doi: 10.21037/tcr-24-2126

Figure Lengend Snippet: Expression of CD4 and CD20 staining in different groups. (A) In the encephalitis group, CD20 positive lymphocytes infiltration into the squamous epithelium was apparent (the arrow points to the squamous epithelium). (B) In the encephalitis group, CD4 positive lymphocytes infiltration into the squamous epithelium was apparent (the arrow points to the squamous epithelium). (C) In control groups, the distribution of lymphocytes with CD4 positive was more dispersed (the arrow points to the squamous epithelium). (D) In control groups, the distribution of lymphocytes with CD20 positive was more dispersed (the arrow points to the squamous epithelium).

Article Snippet: The main antibodies (Abs) used were rabbit anti-human CD4 monoclonal antibody (dilution 1:100, Boster, China), rabbit anti-human CD20 polyclonal antibody (dilution 1:100, Boster, China), rabbit anti-human NMDAR2A antibody (dilution 1:100, Boster, China), rabbit anti-human NMDAR2B antibody (dilution 1:100, Tri-Eagle, China), rabbit anti-human NMDAR 1 antibody (dilution 1:100, Boster, China).

Techniques: Expressing, Staining, Control

Journal: Nature

Article Title: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

doi: 10.1038/s41586-024-08305-z

Figure Lengend Snippet: a , Swimmer plot for 25 patients with mixed solid tumours treated with escalating doses (DLs) of visugromab (0.3, 1.0, 3.0, 10 and 20 mg kg −1 , once every other week) and nivolumab in last-line treatment, with relapsed or refractory cancer under prior anti-PD-1 or anti-PD-L1 treatment. Data show time course and remission status, with tumour regression (blue; greater than −5%) and PR (light green) as per RECIST 1.1. Broken lines indicate not evaluable (NE). MES, mesothelioma; UCEC, uterine corpus endometrial carcinoma; OMEL, ocular melanoma; CCA, cholangiocarcinoma; MEL, melanoma; RCC, renal cell carcinoma; CUP, cancer of unknown primary origin; OVA, ovarian cancer; TNBR, triple-negative breast cancer; CER, cervical cancer; H&N, head and neck squamous cell carcinoma; CRC, colorectal cancer; BF, backfill; PD, progressive disease; SD, stable disease; RT, radiotherapy; RFA, radiofrequency ablation. b , Fold change of CD4 + FOXP3 − , CD8 + , CD3 + Ki67 + and CD3 + GZMB + T cells in evaluable, sequential biopsies of the above patients at day 14 (visugromab monotherapy) and day 28 (combination) compared to baseline (Bsl). Patients with >2-fold increase are depicted in black and patients with <2-fold increase are depicted in light grey. c , Representative immunohistochemical and immunofluorescence images of tumour area (green square 400 × 400 µm) demonstrating baseline (day 0; upper panel) versus monotherapy (day 14; middle panel) and combination therapy impact (day 28; lower panel), showing increase in CD8 + (purple label; n = 8), CD4 + (yellow label; n = 7), in the left panel, and CD3 + Ki67 + (red label; n = 8) and increase in GZMB synthesis (pink label; n = 5), in the right panel.

Article Snippet: CD4 staining was carried out using a monoclonal rabbit anti-human CD4 antibody (clone SP35; CellMarque; product no. 104R), and FOXP3 was stained using a monoclonal rabbit anti-human FOXP3 antibody (clone SP97; Abcam; product no. Ab99963).

Techniques: Immunohistochemical staining, Immunofluorescence

Journal: Nature

Article Title: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

doi: 10.1038/s41586-024-08305-z

Figure Lengend Snippet: a , Volcano plot presenting differentially expressed genes in biopsies on day 14 of visugromab monotherapy compared to pretreatment biopsies in participants with >2-fold increase in CD8 + and CD4 + T cells ( n = 5). P values are from two-sided moderated t- test using limma. Dashed vertical lines, −1.5 and +1.5 fold change. Dashed horizontal line, P = 0.05. b , Reactome pathway analysis shows that significantly upregulated genes from the PanCancer IO 360 panel in a are part of important inflammation-related pathways. P values are from two-sided Fisher’s exact test and adjusted according to the Benjamini–Hochberg method ( P adj ). Numbers of PanCancer IO 360 panel genes in the respective pathway (second number to right of each bar) and of significantly upregulated genes in the respective pathway (first number to right of each bar) are indicated. Grey vertical line, P adj = 0.1. OAS, oligoadenylate synthetases. c , Significant induction and maintenance of CXCL9 following treatment for 6 weeks in the blood of participants with NSCLC, HCC and UC in the phase 2a study. P values are reported from repeated-measures one-way analysis of variance (ANOVA) with Geisser–Greenhouse correction, corrected for multiple comparisons by Dunnett’s test. d , Baseline CXCL9 levels of participants with best overall response according to RECIST 1.1. P values are reported from two-tailed Mann–Whitney test. e , Heat map representing higher mean values (pg ml −1 ) of CXCL9 following treatment in participants with best overall response of PR and CR (lower row) compared to participants with best overall response of PD and SD (upper row). For the box plots in c , d : centre line, median; box, IQR; whiskers, 1.5 × IQR; outliers are depicted individually. C1D1, cycle 1 day 1; C1D2, cycle 1 day 2; C2D1, cycle 2 day 1; C3D1, cycle 3 day 1.

Article Snippet: CD4 staining was carried out using a monoclonal rabbit anti-human CD4 antibody (clone SP35; CellMarque; product no. 104R), and FOXP3 was stained using a monoclonal rabbit anti-human FOXP3 antibody (clone SP97; Abcam; product no. Ab99963).

Techniques: Two Tailed Test, MANN-WHITNEY

Journal: Nature

Article Title: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

doi: 10.1038/s41586-024-08305-z

Figure Lengend Snippet: (a) Exhaustion markers PDCD1, HAVCR2 and LAG3 are not differentially expressed in pre-(baseline) ( n = 6) and on-treatment (D14) ( n = 5) biopsies following visugromab therapy in trial participants with >2-fold (IMM) and participants with <2-fold (NOIMM) increase in CD8 + and CD4 + T cells. Boxplots black line, median; red line, mean; box, IQR; ns, not significant, (P > 0.5 from two-sided Wilcoxon rank sum test). (b) Volcano plot presenting differentially expressed genes (NS = no significant change) in biopsies on day 14 of visugromab monotherapy compared to pre-treatment biopsies in participants with <2-fold (NOIMM) increase in CD8+ and CD4 + T cells. P values are from moderated t-test using limma.

Article Snippet: CD4 staining was carried out using a monoclonal rabbit anti-human CD4 antibody (clone SP35; CellMarque; product no. 104R), and FOXP3 was stained using a monoclonal rabbit anti-human FOXP3 antibody (clone SP97; Abcam; product no. Ab99963).

Techniques:

Journal: Nature

Article Title: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

doi: 10.1038/s41586-024-08305-z

Figure Lengend Snippet: a , CD4 + FOXP3 + T cell density, CD4 + FOXP3 − T cell density and CD3 + Ki67 + T cell density are significantly reduced in tumour biopsies from patients in phase 1 and 2 with serum GDF-15 (sGDF-15) of >1.5 ng ml −1 . P values are from two-sided Mann–Whitney test. b , In baseline tumour tissue with very high CD8 + T cell infiltration from patients in phase 1 and 2, low (pro-)GDF-15 expression is observed. P value is reported from two-sided Mann–Whitney test. c , TME characterization by PD-L1 tumour proportion score (TPS) and CD8 + T cell density (cells mm −2 ) in biopsies from patients in phase 1 and 2 before treatment ( n = 97); PR and CR are highlighted in green.

Article Snippet: CD4 staining was carried out using a monoclonal rabbit anti-human CD4 antibody (clone SP35; CellMarque; product no. 104R), and FOXP3 was stained using a monoclonal rabbit anti-human FOXP3 antibody (clone SP97; Abcam; product no. Ab99963).

Techniques: MANN-WHITNEY, Expressing

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: Flow cytometry charts from one representative BCC, one SCC, and one NS sample. In the dot plots, percentages denote the frequency of events/cells within selected regions relative to the total depicted events. Shown are percentages of ( A ) CD4+ and CD8+ cells within CD3+ cells, ( B ) CD45RO+ cells within the CD3+ population, ( C ) IFN-γ+ cells within the CD4+ population (Th1 cells), ( D ) IL-4+ cells within the CD4+ population (Th2 cells), and ( E ) IL-17+ cells within the CD4+ population (Th17 cells). In ( F ), the graphs depict the combined forward scatter plot (FSC-A) of lymphocytes, featuring the expected dispersion of cell sizes (y axis) and concurrent staining for the TCR γδ (GD). The lymphocyte population was gated from a prior compound scatter plot (forward plus side scattering). Also shown are the percentages of IFN-γ+ cells within the CD8+ population ( G ). In the graphs, y and x axes depict the logarithm of relative fluorescence intensities.

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques: Flow Cytometry, Dispersion, Staining, Fluorescence

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: Major CD3+ T cell subpopulations in NMSCs compared with normal skin (flow cytometry analysis—gating for CD3+ T cells).

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques: Flow Cytometry

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: NMSCs feature altered percentages of CD4 and CD8 T cell subpopulations relative to NS controls. ( A – J ) Graphs displaying frequencies and ratios of T cell subsets in BCCs, SCCs, and NS. ( A ) Percentages of CD4+ and CD8+ cells after gating for CD3+ T cells. ( B ) Ratios between CD4+ and CD8+ T cells. ( C ) Percentage of CD45RO+ cells after gating for CD3+ T cells. ( D ) Percentages of Th1 and Th2 cells after gating for CD4+ T cells. ( E ) Ratios between Th1 and Th2 T cells. ( F ) Percentages of IFNγ+ T cells after gating for CD8+ T cells. ( G ) Percentages of Th17 and FoxP3+ Treg cells after gating for CD4+ T cells. ( H ) Ratios between CD8+ T cells and Treg cells. ( I ) Percentages of T cells expressing the γδ receptor after gating for CD3+ T cells. ( J ) Ratios between Th17 and Treg cells. Horizontal bars represent medians, * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques: Expressing

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: Major CD4+ T cell subpopulations in NMSCs compared with normal skin (flow cytometry analysis—gating for CD4+ T cells).

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques: Flow Cytometry

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: Semi-quantitative assessment of T cells in BCCs, SCCs, and normal skin.

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques:

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: Infiltrates of CD3+, CD4+, CD8+, and FoxP3+ T cells are denser in BCCs and SCCs than in NS and are mainly localized at the tumor periphery. ( A – D ) Graphs showing IHC scores in BCCs and SCCs compared to NS for ( A ) CD3+, ( B ) CD4+, ( C ) CD8+, and ( D ) FoxP3+ T cells. ( E – H ) Graphs representing the spatial distribution of the infiltrates of ( E ) CD3+, ( F ) CD4+, ( G ) CD8+, and ( H ) FoxP3+ T cells at the inner areas of the tumor ( In ) and at the tumor periphery ( P ). Horizontal bars represent medians, **** p < 0.0001.

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques:

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: BCCs and SCCs feature a dense stromal T cell infiltrate. Shown are contiguous sections of exemplary samples of BCC stained for CD3 (( A ), 50×; ( B ), 200×), CD4 (( C ), 50×; ( D ), 200×), CD8 (( E ), 50×; ( F ), 200×), and FoxP3 (( G ), 50×; ( H ), 200×), and of SCC, also stained for CD3 (( I ), 50×; ( J ), 200×), CD4 (( K ), 50×; ( L ), 200×), CD8 (( M ), 50×; ( N ), 200×), and FoxP3 (( O ), 50×; ( P ), 200×). Note the overall paucity of T cells within the tumoral epithelia. Magnifications provided correspond to original magnifications.

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques: Staining

Journal: Cells

Article Title: Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study

doi: 10.3390/cells13110964

Figure Lengend Snippet: T cell populations in normal skin. Shown are contiguous sections of normal skin samples stained for CD3 (( A ), 50×; ( B ), 200×), CD4 (( C ), 50×; ( D ), 200×), CD8 (( E ), 50×; ( F ), 200×), and FoxP3 (( G ), 50×; ( H ), 200×). Lymphoid infiltrates are scarce and mainly circumscribed to the perivascular and perifollicular areas. Magnifications provided correspond to original magnifications.

Article Snippet: Antibodies used in this study were rabbit polyclonal anti-human CD3 (cat. A045229-2, Agilent Technologies Singapore, Singapore), rabbit monoclonal anti-human CD4 (clone SP35, Ventana Medical Systems, Roche Tissue Diagnostics, Tucson, AZ, USA), mouse monoclonal anti-human CD8 (clone 4B11, cat. PA0183, Leica Biosystems, Newcastle, UK), and rabbit monoclonal anti-human FoxP3 (clone SP97, Life Technologies Europe BV, Bleiswijk, Netherlands).

Techniques: Staining

Journal: Cancer Imaging

Article Title: Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study

doi: 10.1186/s40644-024-00698-4

Figure Lengend Snippet: Baseline characteristics of the patients ( n = 119)

Article Snippet: Immunohistochemical staining of CD4, CD8, CD163, IL-6, and MMP-11 was conducted using the following primary antibodies: monoclonal rabbit anti-human CD4 (clone SP35, catalog number: 7,904,423; Ventana Medical Systems, Tucson, AZ, USA), monoclonal mouse anti-human CD8 (clone C8/144B, catalog number: IR623; Dako, Carpinteria, CA, USA), monoclonal mouse anti-human CD163 (clone OTI2G12, catalog number: ab156769; Abcam, Cambridge, UK), polyclonal rabbit anti-human IL-6 (catalog number: ab6672; Abcam), and monoclonal rabbit anti-human MMP-11 (clone SN74-08, catalog number: NBP2-67670; Novus Biologicals, Centennial, CO, USA).

Techniques: Expressing, Adjuvant

Journal: Cancer Imaging

Article Title: Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study

doi: 10.1186/s40644-024-00698-4

Figure Lengend Snippet: An 81-year-old woman underwent FDG PET/CT for staging work-up of colon cancer in the proximal transverse colon. In maximal intensity projection ( a ) and transaxial PET/CT ( b ) images, the tumor lesion (arrows) showed intensely increased FDG uptake with a maximum standardized uptake value (SUV) of 17.79. Using Nestle’s adaptive threshold method, the tumor lesion (purple color) was automatically delineated on PET images ( c ), and the SUV intensity histogram of the tumor lesion was made ( d ). Metabolic tumor volume, total lesion glycolysis, coefficient of variation, entropy, and uniformity extracted from the tumor lesion were 97.52 cm 3 , 1000.17 g, 0.233, 4.66, and 0.047, respectively. Increased FDG uptake of the bone marrow (BM) and spleen was observed in transaxial ( e ) and sagittal ( f ) PET/CT images, revealing BM SUV of 2.09, spleen SUV of 2.06, BLR of 1.00, and SLR of 0.98. The patient underwent curative surgery, and immunohistochemical analysis of the surgical specimen demonstrated grade 0 of CD4 + cell infiltration ( g ), grade 0 of CD8 + cell infiltration ( h ), grade 2 of CD163 + cell infiltration ( i ), grade 2 of interleukin-6 expression ( j ), and grade 1 of matrix metalloproteinase-11 expression ( k ) in tumor tissue. The patient experienced cancer recurrence 7 months after the surgery

Article Snippet: Immunohistochemical staining of CD4, CD8, CD163, IL-6, and MMP-11 was conducted using the following primary antibodies: monoclonal rabbit anti-human CD4 (clone SP35, catalog number: 7,904,423; Ventana Medical Systems, Tucson, AZ, USA), monoclonal mouse anti-human CD8 (clone C8/144B, catalog number: IR623; Dako, Carpinteria, CA, USA), monoclonal mouse anti-human CD163 (clone OTI2G12, catalog number: ab156769; Abcam, Cambridge, UK), polyclonal rabbit anti-human IL-6 (catalog number: ab6672; Abcam), and monoclonal rabbit anti-human MMP-11 (clone SN74-08, catalog number: NBP2-67670; Novus Biologicals, Centennial, CO, USA).

Techniques: Positron Emission Tomography-Computed Tomography, Immunohistochemical staining, Expressing

Journal: Cancer Imaging

Article Title: Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study

doi: 10.1186/s40644-024-00698-4

Figure Lengend Snippet: Distribution of metabolic tumor volume (MTV) ( a ) and total lesion glycolysis (TLG) ( b ) according to CD4 + cell infiltration grade in tumor tissue. Distribution of entropy ( c ) and mean standardized uptake value of the bone marrow (BM SUV) ( d ) according to CD163 + cell infiltration grade in tumor tissue. Distribution of TLG ( e ) and uniformity ( f ) according to interleukin-6 (IL-6) expression grade in tumor tissue

Article Snippet: Immunohistochemical staining of CD4, CD8, CD163, IL-6, and MMP-11 was conducted using the following primary antibodies: monoclonal rabbit anti-human CD4 (clone SP35, catalog number: 7,904,423; Ventana Medical Systems, Tucson, AZ, USA), monoclonal mouse anti-human CD8 (clone C8/144B, catalog number: IR623; Dako, Carpinteria, CA, USA), monoclonal mouse anti-human CD163 (clone OTI2G12, catalog number: ab156769; Abcam, Cambridge, UK), polyclonal rabbit anti-human IL-6 (catalog number: ab6672; Abcam), and monoclonal rabbit anti-human MMP-11 (clone SN74-08, catalog number: NBP2-67670; Novus Biologicals, Centennial, CO, USA).

Techniques: Expressing